All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

EHA 2022

Share:

Jul 30, 2022

X post image

11 Aug 2022

Catch up on the results of the IFM2018-04 study from #EHA2022 of transplant-eligible patients with newly diagnosed multiple #myeloma treated with tandem ASCT and quadruplet therapy 👇 #mmsm
⭐ https://t.co/2sVT6XvbLl ⭐

X post image

27 Jul 2022

NEWS🚨
EMA’s CHMP recommend the conditional approval of teclistamab in Europe for RRMM. Read a summary of the phase I/II MajesTEC-1 trial to see the latest data on what might be the first BCMA/CD3 bispecific Ab approved for #myeloma
#mmsm #EHA2022 #mednews
https://t.co/Uw48GL7HgQ

X post image

21 Jun 2022

Chcek out our twitter moment from #EHA2022, which includes all our updates from the congress 👀👇

https://t.co/SMgiwwvZrH

X post image

12 Jun 2022

We hope you’ve enjoyed keeping up with our live #EHA2022 congress updates! 🎓

Keep an eye on our socials for post-congress summaries and key insights! 📲

#EHA2022 #medicalcongress #cancerawareness

X post image

12 Jun 2022

CONGRESS | #EHA2022 | Median time to response was < 1 months. MTD not reached. BCMA-ADC treated patients were included. #mmsm

X post image

12 Jun 2022

CONGRESS | #EHA2022 | @JoshuaRichterMD @TischCancer @IcahnMountSinai presents phase 1 results of REGN5458 in RR #myeloma. Data suggest acceptable safety profile and promising efficacy in heavily pre-treated patients. No Gr3 ICANS or ≥3 CRS, two DLTs. ORR 75%. #mmsm

X post image

12 Jun 2022

RT @lymphomahub: CONGRESS #EHA2022 LBA:
Isabelle van Zeventer @umcg, presents the largest study on clonal evolution in the general populati…

X post image

12 Jun 2022

CONGRESS | #EHA2022 | Next steps in DETERMINATION trial: Additional MRD analyses, evaluation of patient- and disease-related factors including race, whole-genome sequencing, additional QoL analyses #mmsm

X post image

12 Jun 2022

CONGRESS #EHA2022 LBA: Paul Richardson, @DanaFarber on ph3 DETERMINATION trial. Significantly longer PFS with RVd+ASCT vs RVd alone. No OS benefit after >6 years follow-up. Similar ORR rates (97.5% vs 95%). RVd+ASCT was generally manageable but sign. ↑ rates of tox #mpnsm

X post image

12 Jun 2022

It’s the last day of EHA!
Don’t miss out on closing interviews, key insights, and live updates!
Sessions covered👇
- Late-breaking abstracts
- R/R myeloma:BCMA-directed therapies
- Immune response and infection in hematology - Clinical
#EHA2022 #medicalcongress #cancerawareness

X post image

11 Jun 2022

CONGRESS #EHA2022 | @RobertoMinaMD, University of Torino presented innovative approaches for the treatment of MM. He discussed about the novel triplets & ASCT in NDMM
#myeloma #mmsm

X post image

11 Jun 2022

CONGRESS #EHA2022 | @DonkNiels presented innovative approaches for the treatment of MM. Novel immunotherapies CAR-T and BsABs were discussed. Choice of treatment depends on various factors: tumor, patient, & logistics-dependent factors.
#myeloma #mmsm

X post image

11 Jun 2022

CONGRESS #EHA2022 | Xavier Leleu from Hospital La Miletrie discussed the different aspects of MRD in MM: biological tools, clinical impact, clinical trials & treatment modifications based on MRD
#myeloma #mmsm

X post image

11 Jun 2022

POSTER | #EHA2022 | Efstathios Kastritis et al. demonstrated that belamaf monotherapy off-label in pts with RR AL amyloidosis induced rapid, clinically meaningful responses with a manageable safety profile #mmsm #myeloma

X post image

11 Jun 2022

CONGRESS | #EHA2022 | Cyrille Touzeau @CHUnantes talks on teclistamab in pts previously treated with a BCMA-targeted tx from MajesTEC-1 trial
- ORR: 52.5%, early, durable responses deepened over time
- MRD neg: 17.5%
- Good tolerability w/o dose reductions/discontinuations #mmsm

X post image

11 Jun 2022

CONGRESS | #EHA2022 | Results were reported from two different dose levels, 450 mcg SC QW and 800 mcg SC Q2W. Safety, efficacy, PK and PD profiles were comparable. #mmsm

X post image

11 Jun 2022

CONGRESS #EHA2022 | @MinnemaMonique, @UMCUtrecht presents updated data on talquetamab, GPRC5D and CD3 bispecific antibody, from MonumenTAL-1 trial
The most common AEs were CRS, skin-related AEs and dysgeusia. No treatment-related deaths. Durable responses deepened over time #mmsm

X post image

11 Jun 2022

CONGRESS | #EHA2022 | Anna Carolina Hasselbach Riley, Rigshospitalet Copenhagen, shares phase I results for RG6234, a GPRC5D bispecific antibody, in RR #myeloma
- A novel 1:1 configuration
- CRS reported in 80% (mostly Gr1). Gr3 CRS in 1 patient
- No fatal AE.
- ORR 71.4%.#mmsm

X post image

11 Jun 2022

Keep an eye on our Twitter page!
We will be bringing you live updates during our live coverage of @EHA_Hematology congress!
Today's sessions: Innovations in care, RRMM: Antibody-based therapies, Gene therapy and cellular immunotherapy
#EHA2022 #medicalcongress #cancerawareness

X post image

10 Jun 2022

POSTER | #EHA2022 | Rin Nakamura et al. showed that reduced levels of soluble BCMA following cevostamab treatment led to improved response. sBCMA dynamics may be a potential tool for early disease monitoring and identification of response in RRMM #myeloma #mmsm

X post image

10 Jun 2022

CONGRESS #EHA2022 | Heinz Ludwig, Wilhelminen Cancer Research Institute, presents non-inferiority study results of KTd vs KRd in #myeloma
- KTd is non-inferior to KRd
- no significant differences in response, PFS and OS
- High immune score correlates with worse outcome #mmsm

X post image

10 Jun 2022

CONGRESS | #EHA2022 | Evangelos Terpos, @uoaofficial, summarizes preliminary phase 1/2 data of belemaf-Rd in tranplant-ineligible ND #myeloma
- manageable safety profile, low severe ocular AEs
- Rapid/clinically meaningful responses
- Gr 3/4 ocular TEAEs in 8.3% of pts #mmsm

X post image

10 Jun 2022

CONGRESS | #EHA2022 | Cyrille Touzeau @CHUNantes presents results of phase II IFM2018-04 trial inv. Dara-KRd induction in high-risk #myeloma.
- ORR: 96%
- MRD neg: 62%
- Well tolerated with no new safety signals and low grade of Grade 3-4 TRAEs
- Longer follow-up is needed #mmsm

X post image

10 Jun 2022

CONGRESS | #EHA2022 | Dominik Dytfeld @PUMS_tweets presents results of ATLAS trial, the first phase 3 trial investigating post-transplant KRd vs Len maintenance in #myeloma
- PFS: 59 months with KRd (vs 41 months with Len)
- OS benefit and QoL need longer-term follow-up #mmsm

X post image

10 Jun 2022

The @MM_Hub will be virtually covering the sessions on newly diagnosed multiple myeloma, monoclonal gammopathies, gene therapy, cellular immunotherapy & vaccination.

Stay tuned for live updates, key insights, and interview coverage!

#EHA2022 #medicalcongress #cancerawareness

X post image

7 Jun 2022

The @MM_Hub will be covering the EHA 2022 Congress!

The first ever hybrid @EHA_Hematology congress, where we will be attending online and in Vienna!

Keep an eye on our socials for live updates throughout the day! 🗣💻

#EHA2022 #medicalcongress #cancerawareness

X post image

7 Jun 2022

To help navigate the exciting content being presented at the #EHA2022 Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma. Check it out 👇
https://t.co/nQv8dvJtxy

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022 European Hematology Association

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox